Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of GS-1206 in Adults With Solid Tumors
NCT07703878 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of GS-1206 in Adults With Solid Tumors
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- July 17, 2026
- Completion date
- September 30, 2029
- Enrollment
- 302 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor